2-TIP QANDLI DIABET VA SEMIRISH KONTEKSTIDA LIPOPROTEIN(A): MUAMMONING ZAMONAVIY HOLATI
Keywords:
lipoprotein(a), 2-tip qandli diabet, semirish, LPA geni, qoldiq kardiovaskulyar xavfAbstract
Maqsad. Lipoprotein(a) [Lp(a)] biologiyasi, genetik determinatsiyasi va klinik ahamiyati bo‘yicha zamonaviy ma‘lumotlarni umumlashtirish, uning 2-tip qandli diabet (QD2) va semirish bilan bog‘liqligiga urg‘u berilgan holda, shuningdek etnik o‘zbeklarda Lp(a) ni o‘rganishning dolzarbligini asoslash.
Materiallar va usullar. Ushbu mavzu bo‘yicha PubMed, Google Scholar ma‘lumotlar bazalari, shuningdek «Cardiology of Uzbekistan» jurnali va unga yaqin nashrlardagi maqolalar asosida adabiyotlar sharhi o‘tkazildi.
Natijalar. Lp(a) — genetik jihatdan determinlangan, mustaqil va sabab bo‘luvchi ateroskleroz kardiovaskulyar kasallik xavf omili hisoblanadi. Uning QD2 bilan bog‘liqligi noaniq, qisman paradoksal xarakterga ega: Lp(a) ning past konsentratsiyasi QD2 rivojlanish xavfining oshishi bilan bog‘liq, holbuki yuqori konsentratsiyalar allaqachon diabetga chalingan bemorlarda kardiovaskulyar xavfga mustaqil hissa qo‘shishda davom etadi. Lp(a) tarqalishi va uning kardiometabolik omillar bilan aloqadorligi etnik guruhlar o‘rtasida sezilarli farq qiladi, bu esa populyatsion chegara qiymatlarni universal bo‘lishini istisno etadi. O‘zbekistonda bunday tadqiqotlar hozirgacha o‘tkazilmagan.
Xulosa. Lp(a) tarqalishini, uning QD2, semirish va LPA geni variantlari bilan bog‘liqligini etnik o‘zbeklarda kompleks o‘rganish yuqori ilmiy yangilik va amaliy ahamiyatga ega bo‘lib, qoldiq aterogen xavfni baholashning mahalliy yondashuvlarini ishlab chiqish uchun muhimdir
Downloads
References
1. Biolo M, Portinari C, Goffi C, et al. Focus on lipoprotein(a). Eur Heart J Suppl. 2026;28:v181–v186.
2. Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43(39):3925–3946. https://doi.org/10.1093/eurheartj/ehac361
3. Coassin S, Kronenberg F. Lipoprotein(a) beyond the kringle IV repeat polymorphism: the complexity of genetic variation in the LPA gene. Atherosclerosis. 2022;349:17–35.
4. Bekbossynova M, Aripov M, Ivanova-Razumova T, Kali A, Tleubayeva D, Daniyarova G, Goncharov A. Proposing new lipoprotein (a) cut off value for Kazakhstan: pilot study. Front Cardiovasc Med. 2024;11:1468566.
5. Bekbossynova M, Ivanova-Razumova T, Myrzakhmetova G, Andossova S, Kali A, Sailybayeva A, Saliev T. Ethnic Variation in Lipoprotein(a) Levels in the Kazakhstan Population. J Clin Med. 2025;14(17):6336. https://doi.org/10.3390/jcm14176336
6. Алиева Р.Б., Шек А.Б., Абдуллаева А.А. и др. Половые различия в 5-летнем риске больших сердечно-сосудистых событий у больных ишемической болезнью сердца и повышенным уровнем липопротеида(а). Российский кардиологический журнал. 2025;30(3):6019. https://doi.org/10.15829/1560-4071-2025-6019
7. Жемуратова Р.Э., Шек А.Б. Значение липопротеина(а) в развитии сердечно-сосудистых заболеваний. Cardiology of Uzbekistan. 2025;2(2):152–158. https://doi.org/10.70626/cardiouz-2025-2-00047
8. Corral P, Matta MG, Schreier L. Are lipoprotein(a) levels decreased in insulin resistance and type 2 diabetes? Curr Opin Lipidol. 2025 (Epub ahead of print).
9. 2024: the year in cardiovascular disease – the year of lipoprotein(a). Research advances and new findings. Arch Med Sci. 2025.
10. Wang T. Association between lipoprotein(a) plasma levels and diabetic nephropathy in Han Chinese patients with type 2 diabetes mellitus. PLoS One. 2024;19(5):e0299240.
11. Association of apolipoproteins and lipoprotein(a) with metabolic syndrome: a systematic review and meta-analysis. Lipids Health Dis. 2023.
12. Association of Lipoprotein A rs10455872 Polymorphism with Childhood Obesity and Obesity-Related Outcomes. Genes (Basel). 2025.
13. Paige E, Masconi KL, Tsimikas S, Kronenberg F, Santer P, Weger S, Willeit J, Kiechl S, Willeit P. Lipoprotein(a) and incident type-2 diabetes: results from the prospective Bruneck study and a meta-analysis of published literature. Cardiovasc Diabetol. 2017;16:38.
14. Yeung MW, Said MA, van de Vegte YJ, Verweij N, Dullaart RPF, van der Harst P. Associations of very low Lipoprotein(a) levels with risks of new-onset diabetes and non-alcoholic liver disease. Atherosclerosis Plus. 2024;57:19–25.
15. Fu Q, Hu L, Xu Y, Yi Y, Jiang L. High lipoprotein(a) concentrations are associated with lower type 2 diabetes risk in the Chinese Han population: a large retrospective cohort study. Lipids Health Dis. 2021;20:76.
16. Dudum R, Huang Q, Yan XS, Fonseca MA, Jose P, Sarraju A, et al. Lipoprotein(a) levels in disaggregated racial and ethnic subgroups across atherosclerotic cardiovascular disease risk levels. JACC Adv. 2024;3(6):100940.
17. Stürzebecher PE, Uttinger KL, Vogel M, Schlingmann M, Ceglarek U, Isermann B, Kiess W, Körner A, Laufs U. Lipoprotein(a) serum concentrations in children in relation to body mass index, age and sex. Pediatr Res. 2024;96(1):177–183.
